{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:40:22Z","timestamp":1793932822946,"version":"4.8.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002108","name":"Friedreich&apos;s Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.molmed.2023.12.002","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T10:35:16Z","timestamp":1706092516000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia"],"prefix":"10.1016","volume":"30","author":[{"given":"Federica","family":"Pilotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika M.","family":"Chellapandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-2248","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2023.12.002_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21820-1","article-title":"Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials","volume":"12","author":"Mortberg","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.12.002_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nj7526-299a","article-title":"Neurodegenerative disease: brain windfall","volume":"515","author":"Gammon","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.12.002_bb0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3233\/JAD-180275","article-title":"Quality of life, care resource use, and costs of dementia in 8 European countries in a cross-sectional cohort of the Actifcare Study","volume":"66","author":"Handels","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.molmed.2023.12.002_bb0020","first-page":"e105","article-title":"Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.molmed.2023.12.002_bb0025","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.neuron.2023.05.031","article-title":"Tipping points in neurodegeneration","volume":"111","author":"Simons","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.molmed.2023.12.002_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","article-title":"Friedreich ataxia: the clinical picture","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01938516","article-title":"Ueber degenerative Atrophie der spinalen Hinterstr\u00e4nge","volume":"27","author":"Friedreich","year":"1863","journal-title":"Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF01930976","article-title":"Ueber degenerative Atrophie der spinalen Hinterstr\u00e4nge","volume":"26","author":"Friedreich","year":"1863","journal-title":"Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01878006","article-title":"Ueber degenerative Atrophie der spinalen Hinterstr\u00e4nge","volume":"26","author":"Friedreich","year":"1863","journal-title":"Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0055","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.12.002_bb0060","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","article-title":"Natural history of Friedreich\u2019s ataxia: heterogeneity of neurological progression and consequences for clinical trial design","volume":"99","author":"Rummey","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2023.12.002_bb0065","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","article-title":"Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study","volume":"20","author":"Reetz","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jnc.12327","article-title":"150 years of Friedreich ataxia: from its discovery to therapy","volume":"126","author":"Schulz","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2023.12.002_bb0075","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/0883073812448230","article-title":"Clinical features of Friedreich ataxia","volume":"27","author":"Delatycki","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jnc.12215","article-title":"Prevalence gradients of Friedreich\u2019s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge","volume":"126","author":"Vankan","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2023.12.002_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neurol.2014.03.008","article-title":"Pathophysiological and therapeutic progress in Friedreich ataxia","volume":"170","author":"Puccio","year":"2014","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.molmed.2023.12.002_bb0090","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1089\/hum.2020.264","article-title":"Central nervous system therapeutic targets in Friedreich ataxia","volume":"31","author":"Harding","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2023.12.002_bb0095","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia","volume":"335","author":"D\u00fcrr","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0100","first-page":"101","article-title":"Friedreich ataxia: hypoplasia of spinal cord and dorsal root ganglia","volume":"76","author":"Koeppen","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-010-0675-0","article-title":"Pathology and pathogenesis of sensory neuropathy in Friedreich\u2019s ataxia","volume":"120","author":"Morral","year":"2010","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.molmed.2023.12.002_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02265406","article-title":"Friedreich\u2019s ataxia presenting as cardiac disease","volume":"6","author":"Sharratt","year":"1985","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0115","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1073\/pnas.94.14.7452","article-title":"Evolution of the Friedreich\u2019s ataxia trinucleotide repeat expansion: founder effect and premutations","volume":"94","author":"Coss\u00e9e","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.12.002_bb0120","first-page":"554","article-title":"The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia","volume":"59","author":"Filla","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2023.12.002_bb0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U","article-title":"Friedreich\u2019s ataxia: point mutations and clinical presentation of compound heterozygotes","volume":"45","author":"Coss\u00e9e","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.24595","article-title":"Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia","volume":"79","author":"Galea","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10409230600846058","article-title":"The structure and function of frataxin","volume":"41","author":"Bencze","year":"2006","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5005136","article-title":"Ferroptosis mediated by lipid reactive oxygen species: a possible causal link of neuroinflammation to neurological disorders","volume":"2021","author":"Cheng","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.molmed.2023.12.002_bb0145","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1074\/jbc.R900010200","article-title":"The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress","volume":"284","author":"Nguyen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2023.12.002_bb0150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nchembio.1843","article-title":"Iron-sulfur proteins hiding in plain sight","volume":"11","author":"Rouault","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0155","first-page":"343","article-title":"The indispensable role of mammalian iron sulfur proteins in function and regulation of multiple diverse metabolic pathways","volume":"32","author":"Rouault","year":"2019","journal-title":"Biometals Int. J. Role Met. Ions Biol. Biochem. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0160","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nature08301","article-title":"Function and biogenesis of iron-sulphur proteins","volume":"460","author":"Lill","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.12.002_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tibs.2020.02.001","article-title":"Outlining the complex pathway of mammalian Fe-S cluster biogenesis","volume":"45","author":"Maio","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0170","first-page":"4","article-title":"Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease","volume":"22","author":"Alfadhel","year":"2017","journal-title":"Neurosci. Riyadh Saudi Arab"},{"key":"10.1016\/j.molmed.2023.12.002_bb0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fphar.2014.00130","article-title":"Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation","volume":"5","author":"Martelli","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0180","doi-asserted-by":"crossref","DOI":"10.1042\/NS20180060","article-title":"Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease","volume":"2","author":"Clark","year":"2018","journal-title":"Neuronal Signal"},{"key":"10.1016\/j.molmed.2023.12.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia \u2013 pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2023.12.002_bb0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2013.02.008","article-title":"Regulation of Nrf2-an update","volume":"66","author":"Niture","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0195","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bcp.2012.11.016","article-title":"The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation","volume":"85","author":"Bryan","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0200","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/ijms21030916","article-title":"The NRF2 signaling network defines clinical biomarkers and therapeutic opportunity in Friedreich\u2019s ataxia","volume":"21","author":"La Rosa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0205","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/acel.12482","article-title":"Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period","volume":"15","author":"Corenblum","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.molmed.2023.12.002_bb0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev-pharmtox-010818-021856","article-title":"Modulating NRF2 in disease: timing is everything","volume":"59","author":"Dodson","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fncel.2019.00356","article-title":"Nrf2 induction re-establishes a proper neuronal differentiation program in Friedreich\u2019s ataxia neural stem cells","volume":"13","author":"La Rosa","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0220","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.redox.2017.06.010","article-title":"Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus","volume":"13","author":"Robledinos-Ant\u00f3n","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0225","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-\u03baB response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2023.12.002_bb0230","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.12.002_bb0235","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.3390\/ijms14047853","article-title":"Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons","volume":"14","author":"D\u2019Oria","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0240","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model","volume":"19","author":"Shan","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.molmed.2023.12.002_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101791","article-title":"The Nrf2 induction prevents ferroptosis in Friedreich\u2019s ataxia","volume":"38","author":"La Rosa","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jnc.12322","article-title":"Co-enzyme Q10 and idebenone use in Friedreich\u2019s ataxia","volume":"126","author":"Parkinson","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2023.12.002_bb0255","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jimd.12285","article-title":"Safety and efficacy of (+)-epicatechin in subjects with Friedreich\u2019s ataxia: a phase II, open-label, prospective study","volume":"44","author":"Qureshi","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.molmed.2023.12.002_bb0260","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00415-016-8244-7","article-title":"Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia","volume":"263","author":"Costantini","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0265","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","article-title":"Role of GPX4 in ferroptosis and its pharmacological implication","volume":"133","author":"Seibt","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0275","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.3390\/ijms20205211","article-title":"Targeting NRF2 for the treatment of Friedreich\u2019s ataxia: a comparison among drugs","volume":"20","author":"Petrillo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41419-020-2347-x","article-title":"Correction: Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue","volume":"11","author":"Turchi","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2023.12.002_bb0285","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0773.1975.tb00772.x","article-title":"Methyl mercuric compounds in rat bile","volume":"36","author":"Refsvik","year":"1975","journal-title":"Acta Pharmacol. Toxicol. (Copenh.)"},{"key":"10.1016\/j.molmed.2023.12.002_bb0290","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/ijms22041815","article-title":"Future prospects of gene therapy for Friedreich\u2019s ataxia","volume":"22","author":"Ocana-Santero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.118.252759","article-title":"Ferroptosis as a novel therapeutic target for Friedreich\u2019s ataxia","volume":"369","author":"Cotticelli","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2023.12.002_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2023.12.002_bb0305","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.64.6.803","article-title":"Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia","volume":"64","author":"Di Prospero","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0310","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.apmr.2010.04.007","article-title":"Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia","volume":"91","author":"Drinkard","year":"2010","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.molmed.2023.12.002_bb0315","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0320","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy \u2013 results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.molmed.2023.12.002_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217776","article-title":"Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich\u2019s ataxia","volume":"14","author":"Jasoliya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2023.12.002_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1260977","article-title":"Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich ataxia (DMF-FA-201)","volume":"17","author":"Pane","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nmt-2018-0013","article-title":"Double-blind, randomized and controlled trial of EPI-743 in Friedreich\u2019s ataxia","volume":"8","author":"Zesiewicz","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.molmed.2023.12.002_bb0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.952950","article-title":"Omaveloxolone inhibits IL-1\u03b2-induced chondrocyte apoptosis through the Nrf2\/ARE and NF-\u03baB signalling pathways in vitro and attenuates osteoarthritis in vivo","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0350","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.12.002_bb0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0360","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of Omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0365","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of Omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molmed.2023.12.002_bb0370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0375","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2023.12.002_bb0380","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","article-title":"In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency","volume":"24","author":"Huichalaf","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2023.12.002_bb0385","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.redox.2017.07.006","article-title":"NRF2 deficiency replicates transcriptomic changes in Alzheimer\u2019s patients and worsens APP and TAU pathology","volume":"13","author":"Rojo","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0390","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.biocel.2013.02.012","article-title":"Role of \u03b1-synuclein aggregation and the nuclear factor E2-related factor 2\/heme oxygenase-1 pathway in iron-induced neurotoxicity","volume":"45","author":"He","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0395","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.12.002_bb0400","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fmolb.2019.00116","article-title":"The role of iron regulation in immunometabolism and immune-related disease","volume":"6","author":"Cronin","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.molmed.2023.12.002_bb0405","article-title":"Iron homeostasis and oxidative stress: an intimate relationship","volume":"1866","author":"Galaris","year":"2019","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Res."},{"key":"10.1016\/j.molmed.2023.12.002_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5487\/TR.2011.27.1.001","article-title":"Lipid peroxidation and its toxicological implications","volume":"27","author":"Nam","year":"2011","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.molmed.2023.12.002_bb0415","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bbrc.2016.10.086","article-title":"Lipid peroxidation in cell death","volume":"482","author":"Gaschler","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2023.12.002_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101483","article-title":"Identification of Frataxin as a regulator of ferroptosis","volume":"32","author":"Du","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.molmed.2023.12.002_bb0425","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.freeradbiomed.2023.06.016","article-title":"Frataxin inhibits the sensitivity of the myocardium to ferroptosis by regulating iron homeostasis","volume":"205","author":"Zhang","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2023.12.002_bb0430","article-title":"Clinical trials and clinical research: a comprehensive review","volume":"15","author":"Kandi","year":"2023","journal-title":"Cureus"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423002812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423002812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:28:21Z","timestamp":1761463701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491423002812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1471491423002812"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2023.12.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}